<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02434835</url>
  </required_header>
  <id_info>
    <org_study_id>KWA1101</org_study_id>
    <nct_id>NCT02434835</nct_id>
  </id_info>
  <brief_title>Study of Absorption, Metabolism and Excretion Following a Single Oral Dose of [14C]KWA-0711 to Healthy Male Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kissei Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kissei Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the absorption, metabolism and excretion following a
      single oral dose of [14C]KWA-0711 to healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) of total radioactivity, unchanged drug substance and its major metabolites</measure>
    <time_frame>240 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of total radioactivity, unchanged drug substance and its major metabolites</measure>
    <time_frame>240 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative radioactivity recovery in urine and feces</measure>
    <time_frame>240 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Profiles of metabolites in plasma, urine and faeces</measure>
    <time_frame>240 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>240 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <condition>Healthy Male Subject</condition>
  <arm_group>
    <arm_group_label>[14C]KWA-0711</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]KWA-0711</intervention_name>
    <arm_group_label>[14C]KWA-0711</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are male, caucasian, and between 35 and 55 years of age, inclusive.

          -  Subjects who have a body mass index (BMI) between 18.5 and 30.0 kg/m2, inclusive.

          -  Subjects who have a body weight between 50 and 100 kg, inclusive.

          -  Subjects must have regular bowel movements.

        Exclusion Criteria:

          -  Subjects who have an abnormality in heart rate, blood pressure , temperature or
             12-lead ECG.

          -  Subjects who are still participating in a clinical study or who have participated in a
             clinical study involving administration of an investigational drug in the 3 months
             prior to dose administration.

          -  Subjects who have had a clinically significant illness within 4 weeks of dose
             administration as determined by the Investigator.

          -  Subjects who have any clinically significant abnormal laboratory safety findings.

          -  Subjects who have had an X ray or who have participated in any clinical trial
             involving a radiolabelled investigational product or have been exposed to
             radiolabelled substances within 12 months prior to dose administration.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>May 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <last_update_submitted>April 15, 2016</last_update_submitted>
  <last_update_submitted_qc>April 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

